Anti-CD160, Alone or in Combination With Bevacizumab, Is a Potent Inhibitor of Ocular Neovascularization in Rabbit and Monkey Models.
Fiche publication
Date publication
juin 2018
Journal
Investigative ophthalmology & visual science
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BENSUSSAN Armand
Tous les auteurs :
Menguy T, Briaux A, Jeunesse E, Giustiniani J, Calcei A, Guyon T, Mizrahi J, Haegel H, Duong V, Soler V, Brousset P, Bensussan A, Raymond Letron I, Le Bouteiller P
Lien Pubmed
Résumé
To assess the efficacy of the murine first-in-class CL1-R2 monoclonal antibody (mAb) targeting human CD160 (alone or in combination with bevacizumab) by using the rabbit corneal neovascularization (CNV) model, and determine the safety and efficacy of ELB01101, a novel CL1-R2-derived humanized IgG4 mAb, in a monkey model of choroidal neovascularization (ChNV).
Mots clés
Angiogenesis Inhibitors, therapeutic use, Animals, Antibodies, Monoclonal, therapeutic use, Antigens, CD, immunology, Bevacizumab, therapeutic use, Biomarkers, metabolism, Choroidal Neovascularization, diagnosis, Corneal Neovascularization, diagnosis, Disease Models, Animal, Drug Therapy, Combination, GPI-Linked Proteins, immunology, Intravitreal Injections, Macaca fascicularis, Male, Rabbits, Receptors, Immunologic, immunology, Vascular Endothelial Growth Factor A, antagonists & inhibitors
Référence
Invest Ophthalmol Vis Sci. 2018 06 1;59(7):2687-2698